

Supplementary table. 1

Supplementary table 1. Patient and tumor characteristics at the start of checkpoint inhibitor

Characteristic	N	%
Gender		
Male	34	59%
Female	24	41%
Age		
Median	64	
Mean	63	
Range	35 - 79	
Diagnosis		
Invasive adenocarcinoma	41	71%
Squamous cell carcinoma	13	22%
NSCLC NOS	1	2%
Great cell	1	2%
unknown	2	3%
Smoking		
Never	6	10%
Ex	34	59%
Current	11	19%
Ex/current	3	5%
unknown	4	7%
Therapies before start		
Chemotherapy	58	100%
Thoracic radiotherapy (n=56)	22	39%
No. months Nivolumab (n=55)		
Median	4	
Mean	6	
Range	0 – 25	
Best overall response		
Nivolumab		
Complete response	1	2%
Partial response	16	28%
Stable disease	16	28%
Progressive disease	13	21%
Not evaluable/Unknown	13	21%